Call 972-746-2222 Now to Schedule


​Dallas | ft. worth TEXAS

​​​ currently enrolling subjects for

To learn more, complete the form above, and call Research Your Health at (972) 746-2222.

Learn about participating in the Glow Trial for an investigational messenger RNA (mRNA) vaccine aimed at preventing seasonal influenza infection.

What is Seasonal Influenza?
Seasonal influenza is a respiratory illness caused by the influenza virus. This virus infects the lungs and breathing passages and is easily spread from person to person. Every year, seasonal influenza causes: 3 to 5 million cases of severe illness worldwide; up to 650,000 deaths worldwide. Seasonal influenza more severely affects people 65 years of age and older. Learn more about the Glow Trial and how you can join at

Why is Moderna Studying an mRNA Vaccine?
Currently approved seasonal influenza vaccines are usually only up to 60% effective(2). An mRNA vaccine has the potential to offer broader protection by responding to strain changes more quickly, creating stronger immune responses and improving protection in older adults.(3) The Glow Trial is studying the mRNA-1010 investigational vaccine to understand whether it can help your body's immune system protect against seasonal influenza.

Who Can Join?
This clinical trial is looking for adult participants. To join, you must be:
*** 50 years of age or older**
* Able to follow participation instructions
* Not pregnant or planning to become pregnant for at least 3 months following your vaccine visit (as appropriate)
Other criteria may apply in order to be eligible

Interested in Participating?
Ask your healthcare provider or contact the clinical trial site listed below.

Site Staff Name:
Jeffrey Adelglass, M.D., F.A.C.S.
(972) 746-2222

1. World Health Organization. Influenza (seasonal): ask the expert: influenza Q&A. Published november 6, 2018.
2. Belongia EA, Simpson MD, King JP, et al. Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. Lancet Infect Dis. 2016.16(8):942-951. doc10.1016/s1473-3099(16)00129-8
3. Rockman S, Laurie KL, Parkes S, Wheatley A, Barr IG. New technologies for influenza vaccines. Microorganisms. 2020;8(11):1745. UA-62491137-11